Neuromyelitis Optica Clinical Trial
Official title:
An Open Label Trial Evaluating the Efficacy and Safety of Bruton's Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Adult Patients With Neuromyelitis Optical Spectrum Disorders (NMOSDs)
This is an open-label study, to evaluate the efficacy and safety of a BTK inhibitor zanubrutinib in participants with NMOSDs.
This is an open, single-center clinical study to evaluate the efficacy and safety of Zanubrutinib in the treatment of recurrent neuromyelitis optica spectrum disease. Patients were required to be diagnosed with neuromyelitis optic spectrum disease according to the NMOSD diagnostic criteria established by the international NMO Diagnostic Group (IPND) in 2015, and to have had at least two relapses (including first episode) within two years while at least one relapse occurring within the 12 months prior to screening. The AQP4 antibody must be positive during screening. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02283671 -
Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B
|
Phase 1 | |
| Recruiting |
NCT01024985 -
Evaluation of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Oct
|
N/A | |
| Recruiting |
NCT04601142 -
Association Between the Effect of Glucocorticoid Pulse Therapy on Neuromyelitis Optica (NMO) and Gene Polymorphism
|
||
| Completed |
NCT03942952 -
PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes.
|
||
| Recruiting |
NCT05573711 -
Restless Legs Syndrome in People With Neuromyelitis Optica Spectrum Disorder
|
||
| Not yet recruiting |
NCT06118398 -
Efgartigimod in Acute Neuromyelitis Optica Spectrum Disorders
|
||
| Recruiting |
NCT05566769 -
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
|
N/A | |
| Withdrawn |
NCT03829566 -
Autologous Transplant To End NMO Spectrum Disorder
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05403138 -
Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders
|
Phase 2/Phase 3 | |
| Completed |
NCT03350633 -
Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05982925 -
Longitudinal Cortical Demyelination in Multiple Sclerosis and Related Disorders
|
||
| Active, not recruiting |
NCT00445367 -
Biobank For MS And Other Demyelinating Diseases
|
||
| Terminated |
NCT02398994 -
A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis
|
Phase 3 | |
| Withdrawn |
NCT02087813 -
Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses
|
Phase 1 | |
| Terminated |
NCT01339455 -
Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02021825 -
Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders
|
Phase 4 | |
| Active, not recruiting |
NCT04614454 -
High Frequency Impulse Therapy for Neuropathic Pain in NMOSD
|
Phase 2 | |
| Recruiting |
NCT03370965 -
Optic Neuritis Differential Diagnosis Study
|
N/A | |
| Completed |
NCT01777412 -
Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations
|
Phase 1 | |
| Recruiting |
NCT01623076 -
The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
|